After endocrine therapy for postmenopausal early breast cancer, allocation to aromatase inhibitors reduced recurrence at 10 y. Wilcken N. Ann Intern Med 2025;178:JC126.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wilcken N. After endocrine therapy for postmenopausal early breast cancer, allocation to aromatase inhibitors reduced recurrence at 10 y. Ann Intern Med 2025;178:JC126.
PMID: 41183342